Redica Systems Closes Financing to Advance Predictive Quality and Regulatory Intelligence in Life Sciences
PLEASANTON, Calif.--(BUSINESS WIRE)--Redica Systems, a leader in Quality and Regulatory Intelligence for the Life Sciences industry, today announced a financing with participation by Merck Global Health Innovation Fund (MGHIF) along with existing investors Savant Growth and Rock Creek Capital.
The investment will accelerate Redica's expansion of its Catalyst Platform™ and the Redica Supplier Data Network™ (SDN), advancing AI-driven workflows, predictive quality and regulatory intelligence, and supply chain risk management solutions tailored for life sciences organizations.
'This investment strengthens our ability to power predictive quality and data-driven AI programs,' said Michael de la Torre, CEO of Redica Systems. 'Our mission is to empower customers to proactively enhance quality and minimize compliance risks—ultimately improving product safety and driving measurable business performance.'
The financing represents a major milestone in Redica's mission to deliver intelligent, scalable solutions for an increasingly complex regulatory and supply chain environment.
'We are excited to work with Redica Systems to advance their groundbreaking work in predictive intelligence,' said Joe Volpe, Managing Director at Merck Global Health Innovation Fund. 'The ability to securely integrate public and private data is an important piece in the life sciences industry's capacity to monitor and mitigate quality and supply chain risks.'
This collaboration enhances Redica's strong foundation for extracting, enriching, and connecting unstructured data—from regulations and standards to inspections and enforcement—transforming it into structured, actionable intelligence.
Redica Catalyst™ Platform - a purpose-built Enterprise AI regulatory and quality solution for the Life Sciences sector. It uses a multilayered architecture to integrate structured and unstructured data from public and private sources. With capabilities such as Redica ID™ - for entity resolution and integration with master data and Redica DocIQ™ - for processing unstructured data, Catalyst supports predictive quality, compliance, and supply chain oversight with precision and scale. It uniquely blends AI with human-in-the-loop workflows to ensure high data accuracy, actionable insights, and seamless enterprise adoption.
Redica Supplier Data Network™ (SDN) - a transformative data-sharing ecosystem designed to resolve persistent challenges around fragmented supplier risk data. It consolidates proprietary and public datasets to create secure, comprehensive supplier profiles. These profiles integrate seamlessly with Redica ID and feed into the Catalyst engine, powering predictive analytics across the supply chain. Features include shared audit programs, GMP document repositories, and standardized supplier questionnaires—all hosted in a secure environment that promotes cross-enterprise collaboration and reduces redundancy.
About Redica Systems
Redica Systems, headquartered in Pleasanton, California, provides Quality and Regulatory Intelligence (QRI) solutions to life sciences companies worldwide. Using advanced AI and machine learning, Redica's platform aggregates data from over 200 global regulators, delivering actionable insights to help companies optimize compliance, mitigate risk, and enhance operational efficiency. Its flagship solutions, including the Catalyst data platform, RedicaID, DocIQ, and the Redica Supplier Data Network, are designed to solve complex industry challenges with unmatched precision.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Kane Biotech Announces First Quarter 2025 Financial Results
WINNIPEG, Manitoba, May 29, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ('Kane Biotech', 'Kane' or the 'Company') today announces its first quarter 2025 financial results. First Quarter 2025 Financial Highlights (Comparatives Exclude Discontinued STEM Animal Health 'STEM' Operations): Total revenue for the three months ended March 31, 2025 was $412,513 compared to $51,886 in the three months ended March 31, 2024. Revenue in the current quarter consists primarily of contract animal health manufacturing revenue for Dechra Veterinary Products, Inc. Gross profit for the first quarter of 2025 was $42,447, compared to a gross profit of $40,051 for the first quarter of 2024. Total operating expenses for the three months ended March 31, 2025 were $1,203,505 compared to $1,228,153 for the three months ended March 31, 2024. Net loss for the first quarter of 2025 was $(1,218,497) compared to a net loss of ($1,346,825) for the quarter ended March 31, 2024. Kane Biotech's March 31, 2025 Financial Statements and the Management Discussion and Analysis with regards thereto are now available on SEDAR+ and the Company's website. Corporate Update: On April 28, 2025, the Company outlined a restructuring strategy that focuses primarily on the four verticals of is revyve™ biofilm dispersion technology-based wound care product portfolio. On May 5, 2025, the company closed and received the funds related to its previously announced $1.2 million private placement and $1.0 million unsecured loan and has continued to execute on a number of cost reduction initiatives including a reduction in overhead and other areas which will materially reduce monthly operating costs going forward. As part of their commitment to the Company, on May 9, 2025, two insiders of the company, Dr. Robert Huizinga and Mr. Philip Renaud surrendered 1,750,000 and 1,622,095 respectively of their outstanding RSUs for cancellation. Kane Biotech announced on April 28, 2025 that the CEO was no longer with the Company. The former CEO recently filed and served a legal action for $445,000 related to his employment agreement with Kane Biotech. The action will be vigorously defended. 'We are executing on the restructuring strategy announced earlier this year with discipline and focus. This strategy will allow us to create value for shareholders by focusing on commercial opportunities in the US,' said Dr. Robert Huizinga, Interim CEO. 'We have streamlined our operations to preserve cash, strengthened our financial position, and have aligned our resources with our highest-priority programs, namely our revyve™ product line. We remain committed to strengthening our product distributor relationships, advancing our pipeline and delivering long-term value to patients, partners, and shareholders.' About Kane Biotech Kane Biotech is developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds which results in serious clinical outcomes and significant cost. revyve™ addresses both biofilms and wound bacteria. For more information: Dr. Robert Huizinga Ray Dupuis Interim CEO Chief Financial Officer Kane Biotech Inc. Kane Biotech Inc. rhuizinga@ rdupuis@ (780) 970-1100 (204) 298-2200 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Caution Regarding Forward-Looking InformationThis press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company's: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at The Company cautions that the foregoing list of factors that may affect future results is not in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
BioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase Agreement ("APA")
The APA Formalized the February 2024 BioVaxys Acquisition of the Former IMV Inc. Assets VANCOUVER, BC, May 29, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce today that the Company and Horizon Technology Finance Corporation ("Horizon") have executed a follow-on Amendment ("Amendment") to the Asset Purchase Agreement dated February 11th, 2024 ("APA") for acquiring the entire portfolio of assets and intellectual property based on the DPX™ immune educating platform technology developed by Canadian biotechnology company, IMV Inc. Section 12 of the February 11th, 2024 APA is a performance milestone provision for BioVaxys to demonstrate an aggregate capital raise of USD $10M by December 31, 2024. On December 9th, 2024, Horizon and BioVaxys initially amended the APA by agreeing to delete the reference to "December 31, 2024" found in Section 12 and replacing it with the date of "June 30, 2025." This new Amendment of May 29th, 2025, supersedes and replaces the Section 12 terms of the APA so that the net performance milestone required to be raised in any form (including, but not limited to equity, grants, licensing fees, or loans) is now significantly lowered to USD $2,028,636. If BioVaxys is successful in meeting this milestone by September 30, 2025, Section 12 of the APA shall end and be of no further force or effect. As consideration for Horizon amending the APA, BioVaxys agrees to issue to Horizon 2,800,000 share purchase warrants and 1,200,000 share purchase warrants to Powerscourt Investments XXV LP ("Powerscourt"), with each warrant entitling Horizon and Powercourt the purchase of one whole at a purchase price of $0.06 Canadian Dollars per share at any time on or before May 31, 2028. Horizon and Powerscourt are the members/owners of HIMV LLC (70%/30%), the party to the APA. All other terms and conditions of the APA to remain the same. BioVaxys and Horizon have further agreed that Section 7(c)(i) of the APA "Licensing Earn-Out Payments Term" be amended from the original "Eighth anniversary of the Closing Date" found in the last line of Section 7(c)(i) to August 11, 2033. During the Licensing Non-Sales Earn-Out Term, BioVaxys shares a predetermined percentage of net licensing non-sales revenues with Horizon. The "Licensing Non-Sales Earn-Out Term" refers to payments received from an existing licensee or preexisting potential licensee, ending upon the expiration of the last valid claim of a former IMV patent that is the subject of the license agreement to which such existing licensee or preexisting potential licensee is party, and any other payment received under a license agreement, ending on August 11, 2033. About BioVaxys Technology Corp. BioVaxys Technology Corp. ( is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on its DPX™ immune-educating technology platform and its HapTenix© 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated and unique mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, and DPX+rPA for peanut allergy prophylaxis, as well as several viral vaccines. BioVaxys has licensed its patented liposome-based delivery platform to Zoetis, Inc. and SpayVac-for-Wildlife, Inc. for selected animal health applications. BioVaxys common shares are listed on the CSE under the stock symbol 'BIOV', trade on the Frankfurt Bourse (FRA: 5LB), and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn. ON BEHALF OF THE BOARD Signed "James Passin" James Passin, Chief Executive OfficerPhone: +1 740 358 0555 Cautionary Statements Regarding Forward Looking Information This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties. The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Investors are encouraged to read BioVaxys continuous disclosure documents and audited annual consolidated financial statements which are available on SEDAR at Logo - View original content to download multimedia: SOURCE BioVaxys Technology Corp. Sign in to access your portfolio
Business Upturn
3 hours ago
- Business Upturn
Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer
FREMONT, Calif., May 29, 2025 (GLOBE NEWSWIRE) — In a move that underscores its dedication to shaping the future of cell analysis, Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the launch of the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that improves on its flagship Cytek Aurora system. First launched in 2017 to address the limitations of existing flow cytometry technologies, Cytek's Full Spectrum Profiling™ (FSP®) systems have become the spectral technology of choice for researchers worldwide, with over 2,600 peer-reviewed publications citing its use – more than any other spectral flow cytometer. Building on this groundbreaking success, the new Cytek Aurora Evo system has been reengineered to carry forward the proven reliability and reproducibility of the Cytek Aurora system, while introducing high-throughput and automation capabilities to meet the demands of modern research. The Cytek Aurora Evo system utilizes Cytek's FSP technology, continuing to provide the field-tested capability to run large multicolor experiments without compromising data quality, as well as an unparalleled level of assay flexibility. The ability to resolve both small particles and large cells on a single instrument allows scientists to tackle a wider range of applications with confidence. The newly added capabilities of improved sample throughput, automated instrument maintenance, and data harmonization were all added to empower researchers to accelerate discoveries with greater speed and confidence. With increasing demand for high-performance, flexible, and efficient cell analysis tools, the new Cytek Aurora Evo flow cytometer is well-positioned to meet the evolving needs of researchers and further drive the adoption of spectral flow cytometry. Key features and benefits of the new system include: Instrument Standardization: Harmonized instruments allow for consistent, accurate and reproducible biological data across systems, labs and time. Harmonized instruments allow for consistent, accurate and reproducible biological data across systems, labs and time. High-Resolution and Throughput: A unique optical and electronics design enables excellent sensitivity and resolution across flow rates, from low (15 µL/min) to max (200 µL/min). Samples can now be acquired 2x faster than before. A unique optical and electronics design enables excellent sensitivity and resolution across flow rates, from low (15 µL/min) to max (200 µL/min). Samples can now be acquired 2x faster than before. Small Particle Detection : Previously available as an optional upgrade on the Cytek Aurora system, this capability is now built into the new Cytek Aurora Evo flow cytometer, enabling researchers to detect and resolve extracellular vesicles, viruses, bacteria and other nanoparticles. : Previously available as an optional upgrade on the Cytek Aurora system, this capability is now built into the new Cytek Aurora Evo flow cytometer, enabling researchers to detect and resolve extracellular vesicles, viruses, bacteria and other nanoparticles. Automation Capabilities: Minimize instrument maintenance and maximize efficiency. An integrated plate loader supports multiple carrier types, offering flexible user modes for both low carryover and high-throughput needs. Automated startup and shutdown further streamline workflows, reducing downtime while ensuring high-quality, high-resolution data. Recognized as a pioneer in spectral flow cytometry, Cytek's distinctive approach is renowned for its profound influence on advancing the understanding of cell biology, immunology, oncology and targeted therapeutic methodologies. 'Cytek's Aurora and Northern Lights™ systems have helped revolutionize immunology research and single-cell analysis,' said Ming Yan, Ph.D., CTO of Cytek Biosciences. 'Over the years, we have continuously pushed the boundaries of what's possible in spectral flow cytometry. With this latest launch of the Cytek Aurora Evo system, we've integrated these advancements into a powerful, high-throughput workhorse that delivers an unmatched combination of performance, reliability, efficiency and ease of use – enabling more scientists to leverage the full potential of spectral flow cytometry.' The Cytek Aurora Evo system will make its public debut at CYTO 2025, with demonstrations taking place in Cytek's booth. For more information, please visit About Cytek Biosciences, Inc. Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at Cytek's products are for research use only and not for use in diagnostic procedures (other than Cytek's Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union). Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis, Guava and Muse are trademarks of Cytek Biosciences, Inc. In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website ( LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek's website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. These forward-looking statements include statements regarding Cytek's business strategies, product plans and expectations, and market opportunities. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include global geopolitical, economic and market conditions; Cytek's ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek's ability to evaluate its prospects for future viability and predict future performance; Cytek's ability to accurately forecast customer demand and adoption of its products; Cytek's ability to recognize the anticipated benefits of collaborations; Cytek's dependence on certain sole and single source suppliers; competition; market acceptance of Cytek's current and potential products; Cytek's ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek's ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek's ability to increase penetration in its existing markets and expand into adjacent markets; Cytek's ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek's ability to successfully develop and introduce new products; Cytek's ability to maintain, protect and enhance its intellectual property; Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section entitled 'Risk Factors' set forth in Cytek's Quarterly Report on Form 10-Q filed on May 8, 2025 with the SEC, and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek's forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the events and circumstances reflected in the forward-looking statements will occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek's as of any date subsequent to the date of this press release. Media Contact:Stephanie OlsenLages & Associates(949) 453-8080 [email protected]
